Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0022104 (irritable bowel syndrome)
 8,033 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Significantly decreased levels of serumcholinesterase (CHE) were found in acute Crohn's disease (= CD) (3.2 +/- 1.0 KU/L) and acute ulcerative colitis (= UC) (3.54 +/- 1.6 KU/L) as compared to patients with mild or quiescient disease (CD: 5.5 +/- 1.1 KU/L; UC: 5.59 +/- 0.94 KU/L) and healthy controls (5.69 +/- 1.3 KU/L). Suppression of CHE was most evident in Crohn's colitis (2.98 +/- 1.0 KU/L) and extensive UC (2.96 +/- 1.28 KU/L). Intraindividual comparison showed an increase of CHE-levels during treatment with steroids and salicylates. There was no significant correlation to the reduced bodyweight-levels in severe IBD. Best correlations were seen between CHE/albumin (CD: r = +0.61; UC: r = +0.73) and CHE/hematocrit (CD: r = +0.50; UC: r = +0.61) in severe inflammatory bowel disease. The results of a discriminant analysis showed that CHE-levels can predict the degree of activity correctly in the majority of patients with CD and UC. It is suggested that the decrease of serumcholinesterase reflects an inhibition of liver synthesis as an acute phase response-induced by endotoxins and cytokines.
 ...
PMID:[Serum cholinesterases as activity parameters in chronic inflammatory bowel diseases]. 138 Jul 51

Bone densitometry using dual-photon absorptiometry (DPA) or dual-energy x-ray absorptiometry (DXA) has become a standard method for assessing bone mineral content in the spine and other skeletal regions. A projected areal density, referred to as bone mineral density (BMD,g/cm2), is normally calculated to assess regional bone density and strength. We demonstrate that this measure can be misleading when used to compare bones of different sizes due to inherent biases caused by bone thickness differences. For example, assuming that volumetric bone density remains constant and bony linear dimensions are proportional to height, a 20% increase in height would result in a 20% increase in both the thickness and the BMD of any bone. We describe new analysis methods to reduce the confounding effect of bone size, and we introduce a parameter, bone mineral apparent density (BMAD, g/cm3), that better reflects bone apparent density. Using this parameter, we calculate a quantity that serves as an index of bone strength (IBS, g2/cm4) for whole vertebral bodies. These analyses were applied to lumbar spine (L2-4) DXA measurements in a population of women 17-40 years old and appear to offer advantages to conventional techniques.
 ...
PMID:New approaches for interpreting projected bone densitometry data. 157 Jul 58

Indices of bone mass were measured in 23 volunteers weekly over 14-16 weeks using dual-energy x-ray absorptiometry (DEXA) and special-purpose computed tomography (gamma-CT). In vitro, the precision for both systems was excellent (coefficient of variation less than 0.5%). Over 4 months, the precision in vivo (average CV for all subjects) for DEXA measures (BMD, g/cm2, and BMC, g/cm) varied between 0.6 and 1.1%; with gamma-CT it varied from 1.1% for TBD (g/cm3) to 2.2% for CBD (g/cm3). Correlation between the indices of bone mass measured using DEXA and gamma-CT at the ultradistal site was moderate, but these indices were not correlated at the distal third site. When BMD and BMC were derived from the CT index IBD, however, the correlation between these gamma-CT indices and the corresponding DEXA indices was high for both ultradistal and proximal radial sites.
 ...
PMID:Bone mass measurements in the distal forearm using dual-energy x-ray absorptiometry and gamma-ray computed tomography: a longitudinal, in vivo comparative study. 160 26

Most medical specialities have defined medically unexplained syndromes such as fibromyalgia, to categorize patients with prominent but unexplained symptoms. Other such syndromes include irritable bowel syndrome, chronic fatigue syndrome and atypical chest pain. In this chapter we present evidence to suggest that fibromyalgia is not a unique clinical entity, but shares much with these other syndromes. We use historical, clinical and epidemiological evidence to illustrate this idea. The historical data emphasize the essentially arbitrary way in which fibromyalgia developed. The clinical evidence shows the considerable overlap between patients with fibromyalgia and those with other unexplained syndromes. From an epidemiological perspective we emphasize the strong associations between symptoms such as myalgia and fatigue. We conclude by suggesting that fibromyalgia is one of many medically unexplained syndromes which have more similarities than differences between them.
Baillieres Best Pract Res Clin Rheumatol 1999 Sep
PMID:Is fibromyalgia a distinct clinical entity? Historical and epidemiological evidence. 1056 73

Based on clinical studies, the Rome Criteria for the irritable bowel syndrome (IBS) were developed by consensus. The criteria emphasize the presence of abdominal pain and the link between pain and changes in bowel habit. The reliance on a clinical gold standard rather than a biological marker remains one of the major limitations in refining diagnostic criteria. A convincing argument can be mounted that IBS is a disease (a cause of unease). Approximately 10-15% of the general population have IBS, and it affects females more often than males, for unexplained reasons. The annual incidence is probably 1-2%. The onset of symptoms is balanced by symptom loss, so the prevalence remains stable from year to year. Up to one half have symptom improvement over time. Only a minority present for medical care; pain severity as well as psychological distress in part explain health-care seeking. IBS significantly impacts on quality of life. The economic impact is enormous, representing a multi-billion dollar problem in the United States. The development of acceptable, symptom-based diagnostic criteria has advanced the field, stimulating interest in the pathophysiology and targeted pharmacological therapy, which are essential steps if the disease burden is to be reduced.
Baillieres Best Pract Res Clin Gastroenterol 1999 Oct
PMID:Irritable bowel syndrome: definition, diagnosis and epidemiology. 1058 Sep 15

Recently, the small intestine has become the focus of investigation as a potential site of dysmotility in the irritable bowel syndrome (IBS). A number of motor abnormalities have been defined in some studies, and include 'clustered' contractions, exaggerated post-prandial motor response and disturbances in intestinal transit. The significance of these findings remains unclear. The interpretation of available studies is complicated by differences in subject selection, the direct influence of certain symptoms, such as diarrhoea and constipation, and the interference of compounding factors, such as stress and psychopathology. Dysmotility could also reflect autonomic dysfunction, disturbed CNS control and the response to heightened visceral sensation or central perception. While motor abnormalities may not explain all symptoms in IBS, sensorimotor interactions may be important in symptom pathogenesis and deserve further study.
Baillieres Best Pract Res Clin Gastroenterol 1999 Oct
PMID:Disturbances in small bowel motility. 1058 Sep 16

Although there is a wide variability in symptoms, disorders of colonic motility are the most prominent features in irritable bowel syndrome (IBS). Stool weight is within the normal range but many patients appear to have abnormal rectal sensations. Straining even with soft stool is common. Dietary fibre stimulates ileocolonic flow and may induce more symptoms in IBS than normal. There is evidence of increased responsiveness of the IBS colon, both to the effect of eating and to stress. Defaecatory disorders are common and may reflect both increased or decreased rectal sensitivity. The normal colon is quiescent during sleep, but in IBS coma sleep is often abnormal, with more periods of arousal and the colon consequently more active. There is evidence of increased responsiveness to corticotrophin releasing factor, which mediates much of the effect of stress on the gut. Many patients show a sympathetic/vagal imbalance with relative excess of sympathetic influence in keeping with increased levels of psychological stress and anxiety. There is undoubtedly more than one cause of IBS and around 25% appear to develop symptoms after an infectious enteritis. This has effects on the entero-endocrine system which may take many years to subside.
Baillieres Best Pract Res Clin Gastroenterol 1999 Oct
PMID:Disturbances in large bowel motility. 1058 Sep 17

Dysfunction of the sensory system of the gut is now generally believed to be important in the pathophysiology of irritable bowel syndrome (IBS). This disturbance may well account for some of the symptoms of the disorder, such as abdominal pain, by virtue of the fact that intra-lumenal events (e.g. contractions) may be 'sensed' more easily. It can be assessed in the laboratory by a variety of techniques, but usually involves measuring the patient's response to distension of any site of the gut, most commonly the rectum. Hypersensitivity is the most frequent finding, but hyposensitivity can also occur--hypersensitivity does not appear to be specific to any particular pattern of bowel habit, but hyposensitivity does tend to be generally only seen in patients with constipation, especially those with the 'no urge' type. Although there is some evidence to support hypersensitivity being related to enhanced vigilance in some patients, other data suggest that there may be a true alteration in sensory processing. The mechanisms underlying this sensory dysfunction remain to be elucidated, but could involve changes in either the enteric, spinal and/or central nervous systems. Finally, factors such as gender, stress, emotion and infection can all influence the sensitivity of the gut and may therefore play a role in IBS.
Baillieres Best Pract Res Clin Gastroenterol 1999 Oct
PMID:Sensory dysfunction and the irritable bowel syndrome. 1058 Sep 18

The observations that irritable bowel syndrome (IBS) may be precipitated by an acute enteric infection, or occurs commonly in patients in remission from inflammatory bowel disease (IBD) has prompted consideration of inflammation as a putative basis for symptom generation in IBS. In this regard, IBS may follow a pattern of pathogenesis that is similar to asthma--which was once considered a psychosomatic disease. This review examines the basic scientific evidence of a functional interface between the immune and sensory-motor systems of the gut and discusses how this may be relevant to a subgroup of IBS patients. In addition, review will examine the implications of this for the diagnosis and treatment of IBS.
Baillieres Best Pract Res Clin Gastroenterol 1999 Oct
PMID:Putative inflammatory and immunological mechanisms in functional bowel disorders. 1058 Sep 19

Psychosocial factors, as appreciated within the context of the biopsychosocial model, are necessary for understanding the clinical expression of irritable bowel syndrome (IBS) by virtue of their key roles in the development, precipitation and perpetuation of IBS. Addressing psychosocial factors in assessment and management leads to improvement in the clinical outcome for IBS patients. Pertinent management components include adopting a 'care' approach within an ongoing collaborative treatment relationship; offering any psychological or psychiatric intervention as part of a multi-disciplinary treatment approach; providing education and reassurance; and using mental health professionals when indicated.
Baillieres Best Pract Res Clin Gastroenterol 1999 Oct
PMID:The role of psychosocial factors in irritable bowel syndrome. 1058 Sep 20


1 2 3 4 5 6 7 Next >>